Редактирование: ABL1 (раздел)

==Publications==

{{medline-entry
|title=European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32127639
|abstract=The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase ([[CP]]) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in [[CP]]. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% [[BCR]]-[[ABL1]] at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
|mesh-terms=* Aniline Compounds
* Antineoplastic Agents
* Clinical Decision-Making
* Consensus Development Conferences as Topic
* Dasatinib
* Disease Management
* Fusion Proteins, bcr-abl
* Gene Expression
* Humans
* Imatinib Mesylate
* Leukemia, Myelogenous, Chronic, BCR-ABL Positive
* Life Expectancy
* Monitoring, Physiologic
* Nitriles
* Protein Kinase Inhibitors
* Pyrimidines
* Quality of Life
* Quinolines
* Survival Analysis

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214240
}}